News

– Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce – SALT LAKE CITY and ARLINGTON, Va.,...

- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds - SALT LAKE CITY, Nov. 15, 2022 /PRNewswire/ -- Sera Prognostics...

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif., Oct....

First and only broadly clinically validated test to provide accurate and actionable information to help reduce the morbidity, mortality, and costs associated with preterm birth Salt Lake City and...

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Sera...